ArticleASM case reports2025
Flying under the radar: vancomycin heteroresistance in
Article in ASM case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Antimicrobial resistance (AMR) is a global One Health problem and a growing threat to human and animal health. Antimicrobial susceptibility tests (AST) such as the broth-microdilution method (BMD) guide appropriate antimicrobial therapy but may fail to detect various forms of AMR, such as heteroresistance. We report vancomycin treatment failure in a Case Summary: A patient with cloudy PD effluent presented to his local dialysis center. Samples were sent for testing, and empirical treatment with vancomycin and gentamicin was initiated. An Conclusion: Conventional AST (VITEK 2 and BMD) misclassified the isolates as vancomycin susceptible, while population analysis profiling area under the curve confirmed heteroresistance. Whole-genome sequencing did not identify genetic mechanisms for the heteroresistance, with no mutations detected in known resistance-associated genes. This study highlights the limitations of conventional AST and genomic methods for AMR detection, emphasizing the need for further research into cryptic forms of heteroresistance to enhance diagnostic accuracy and improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.